Dreamin’ of Entering a Patent Settlement Agreement in California? What to Know About California’s Reverse Payment Law
Article
A Decade of FTC v. Actavis: The Reverse Payment Framework Is Older, but Are Courts Wiser in Applying It
Article
United States: Pharmaceutical Antitrust 2025
Insight
Global antitrust sustainability heatmap
Webinar
Quarterly Global Merger Control Webinars: FSR Filing Regime, Merger Control and Sustainability and Spain Update
White & Case Quarterly Global Merger Control Update
Article
United States: Pharmaceutical Antitrust 2024
Alert
New Year, New Venue Law: Newly Passed Law Means State Attorneys General Can Avoid Having Their Antitrust Cases Consolidated in Multidistrict Litigation
Article
United States: Pharmaceutical Antitrust 2023
Article
United States: Pharmaceutical Antitrust 2022
Alert
Analysis: FTC Encouraged to Ban or Limit Non-Compete Agreements in July 9, 2021 Executive Order; Breaks With Tradition, And Follows Trend of Heightened Antitrust Focus on Labor Markets
Alert
What Does President Biden’s July 9, 2021 Executive Order on Competition Mean for the Pharma Industry?
Insight
Sweeping US Order on “Promoting Competition”
The new Executive Order includes 72 initiatives instructing more than a dozen federal agencies to consider adopting rules intended to enhance competition.
Alert
House Bill Mandating User Data Portability and Platform Interoperability Could Impact Digital Companies of All Sizes
Insight
What’s next for drug pricing in the US?
New challenges may lie ahead for the pharmaceutical industry
Insight
US antitrust spotlight on the technology industry
Is 2021 a year of change?
Alert
Senator Josh Hawley Joins Growing Number in Congress Proposing Sweeping Antitrust Reform Legislation
